Zelboraf And Yervoy Benefit From Secret Discounts To Pass NICE Barrier
This article was originally published in The Pink Sheet Daily
NICE has recommended Roche’s Zelboraf and BMS’ Yervoy, as expected based partly on undeniable life extension capabilities, but also on secret price discounts offered by both manufacturers.
You may also be interested in...
NICE downgrades BMS’ Yervoy, while Janssen omits filing for all combinations for Invokana, underscoring the need for EU harmonization through HTA/regulator dialogue.
IQWiG reiterates its “considerable added benefit” rating for the melanoma drug, but pricing negotiations will reopen in 2014.
Roche’s Zelboraf and Bristol-Myers Squibb’s Yervoy exceed NICE’s cost-effectiveness limit, but are still waved through as targeting unmet medical need.